To move vascular procedures out of expensive hospitals, the government turbocharged payments to doctors’ offices. Instead of saving money, it started a boom that is making doctors rich and putting patients in danger.
Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of cancer drugs, for $2.4 billion.
Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved.
The legal issue behind Weinstein’s successful appeal is also at the heart of the former President’s hush-money case.
Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved.
Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved.
Physicians, researchers, CEOs, reporters, and more gathered in downtown Boston Wednesday night to celebrate STAT’s 2024 STATUS List, which features 50
AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from partnered medicines,…
Testing conducted by the FDA on pasteurized commercially purchased milk has found genetic evidence of the H5N1 bird flu virus, the agency confirmed Tuesday.
The genetic data point to a single spillover event that probably occurred in late 2023, the analysis by scientists in the U.S. and Europe suggests.
The FTC’s noncompete ban could force sweeping changes in the health care industry, but implementation of the rule will almost certainly be held up by…
